Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Treatment-Related Fatigue Widespread, But Undertreated, Seldom Discussed

July 1, 2001
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 7
Volume 10
Issue 7

BETHESDA, Maryland-Fatigue among cancer patients "is an important problem, and it’s a legitimate topic for clinical investigation," National Cancer Institute Clinical Director Gregory A. Curt, MD, told Oncology News International, lamenting, " I don’t think it’s high on the radar for the physicians."

BETHESDA, Maryland—Fatigue among cancer patients "is an important problem, and it’s a legitimate topic for clinical investigation," National Cancer Institute Clinical Director Gregory A. Curt, MD, told Oncology News International, lamenting, " I don’t think it’s high on the radar for the physicians."

This seems to be borne out by an accounting of the abstracts presented at the annual meeting of the American Society of Clinical Oncology. Of 3,127 abstracts, only 13 focused on cancer-related fatigue. Yet fatigue is the most prevalent side effect of chemotherapy, affecting more people and lasting longer than pain, nausea, and vomiting, according to a telephone survey of 379 cancer patients sponsored by The Fatigue Coalition.

Dr. Curt said that physicians and patients often don’t talk about cancer-related fatigue because they think nothing can be done about it. That’s not true, he countered, and physicians need to start considering options now that pain, nausea, and vomiting are yielding to treatment. Commenting on the survey, he remarked: "Most oncologists thought pain was more important than fatigue, but patients thought fatigue was more important than pain."

Survey Results

The survey was the second conducted by The Fatigue Coalition, a multidisciplinary group of practitioners, researchers, and patient advocates working to develop diagnosis and treatment guidelines. The first survey concluded that fatigue was undertreated and seldom discussed. Major findings of the new study are listed below.

76% of all cancer patients who responded experienced fatigue at least a few days each month during their most recent chemotherapy and 30% were fatigued every day.

91% of patients experiencing fatigue said it prevented a "normal" life and 85% changed their daily routine as a result.

75% of patients who held jobs said fatigue made them change their employment status in ways ranging from taking sick or vacation days to going on disability or quitting work.

65% of all patients who responded said that their fatigue caused a caregiver to take at least 1 day off work in a typical month.

One of the most surprising findings for Dr. Curt was that some patients complained of fatigue as long as 2 years after treatment. He said he does not know the cause.

While most patients (79%) discussed fatigue with their physicians, nearly half (45%) of the patients did not believe anything could be done about their fatigue and 40% said they received no recommendation in response. Among those who did receive recommendations, the most common suggestion was bed rest or relaxation (37%). Yet according to Dr. Curt, rest "is one of the worst things to do. You get deconditioned."

Other suggestions were diet or nutrition (11%), vitamins (7%), and prescription drugs (6%).

Range of Remedies

The problem of fatigue is complex, Dr. Curt acknowledged. Patients are tired because they are sick, and they are receiving strong therapies that can also cause fatigue. Yet fatigue can be addressed, he noted, citing the work of Russell K. Portenoy, MD, of Beth Israel Medical Center in New York City.

Physicians should first try to ascertain why the patient is fatigued, Dr. Curt said. The range of remedies now available includes light exercise, cutting out daytime naps, and creating a nighttime routine around a hot bath and warm milk to promote sound sleep at night. For some patients, treatment of anemia should be considered, Dr. Curt advised. If a patient is taking a narcotic for pain relief, the medication might be titrated to a lower dose or balanced with a stimulant, he said.

Although fatigue is still by and large neglected, Dr. Curt was optimistic that it will receive more attention as other chemotherapy side effects become less onerous. "We are in the same phase of treating cancer-related fatigue, as we were in treating nausea and vomiting 15 years ago and pain 10 years ago." he said "I remember when the first drugs that were really good at treating nausea and vomiting came out, oncologists were really worried that the chemotherapy wasn’t working because the patients weren’t getting sick. Sometimes we associate side effects of our drugs with the good effect of our drugs, but I think that both in pain research and nausea and vomiting research, we’ve shown that the two can be de-linked."

Future cancer patients will seek out oncologists who pay more attention to the patient’s needs, he predicted. Before that can happen, however, Dr. Curt said more research is needed. "Knowing what the most common causes of cancer related fatigue are and then knowing which of those respond best to specific interventions—we don’t have the foggiest notion about that now," he said.

Articles in this issue

NCI to Expand Its Support for Trials of STI-571
Patients and Physicians Differ on Chemotherapy Expectations
Neoadjuvant Weekly Paclitaxel Ups Breast Cancer Pathologic Complete Response Rates
Concurrent Chemoradiotherapy Helps Preserve Larynx
Once-Daily, Rapid-Onset Morphine Offers Alternative for Those in Severe Pain
FDA Issues New Safeguards for Children in Clinical Trials
Decision Board Helps Breast Cancer Patients Assess Chemotherapy Options, Increases Satisfaction
Over 20% of Breast Cancer Patients Risk Recurrence by Not Taking Their Tamoxifen
Selective Serotonin Reuptake Inhibitors Can Successfully Treat Depression But Not Fatigue in Cancer Patients
Leukemia Society Offers Patient Information on Use of STI-571
Hiking Cigarette Prices Discourages Teens From Taking Up the Habit
Consensus Growing for SV40 Role in Some Mesotheliomas
NCI Launches Randomized Trial of Shark Cartilage in NSCLC
Chemotherapy Common at End of Life
Can Cognitive Dysfunction in Breast Cancer Patients Be Prevented?
Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
1 expert is featured in this series.
7 experts are featured in this series.
7 experts are featured in this series.
5 experts are featured in this series
3 panelists
Related Content
Advertisement

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.

Pimicotinib Earns Approval in China for Tenosynovial Giant Cell Tumors

Russ Conroy
December 23rd 2025
Article

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.


Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Daniel C. McFarland, DO;Michelle Riba, MD
December 22nd 2025
Podcast

Daniel C. McFarland, DO, and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.


Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy

Andrea Eleazar, MHS
December 23rd 2025
Article

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.


Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.


Treatment with ceralasertib plus durvalumab was found to be well tolerated among patients enrolled on the phase 3 LATIFY trial.

Ceralasertib Combo Misses OS End Point in Advanced NSCLC Trial

Russ Conroy
December 23rd 2025
Article

Treatment with ceralasertib plus durvalumab was found to be well tolerated among patients enrolled on the phase 3 LATIFY trial.


Achieving Accessible Cancer Care at Tennessee Oncology

Achieving Accessible Cancer Care at Tennessee Oncology

Ariana Pelosci
December 23rd 2025
Article

How John G. Phillips, MD, MPH, and Tennessee Oncology are aiming to expand radiation oncology access in smaller communities across Tennessee.

Related Content
Advertisement

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.

Pimicotinib Earns Approval in China for Tenosynovial Giant Cell Tumors

Russ Conroy
December 23rd 2025
Article

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.


Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Daniel C. McFarland, DO;Michelle Riba, MD
December 22nd 2025
Podcast

Daniel C. McFarland, DO, and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.


Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy

Andrea Eleazar, MHS
December 23rd 2025
Article

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.


Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.


Treatment with ceralasertib plus durvalumab was found to be well tolerated among patients enrolled on the phase 3 LATIFY trial.

Ceralasertib Combo Misses OS End Point in Advanced NSCLC Trial

Russ Conroy
December 23rd 2025
Article

Treatment with ceralasertib plus durvalumab was found to be well tolerated among patients enrolled on the phase 3 LATIFY trial.


Achieving Accessible Cancer Care at Tennessee Oncology

Achieving Accessible Cancer Care at Tennessee Oncology

Ariana Pelosci
December 23rd 2025
Article

How John G. Phillips, MD, MPH, and Tennessee Oncology are aiming to expand radiation oncology access in smaller communities across Tennessee.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.